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Abstract
Objective: Moderate to severe irreversible mitral regurgitation secondary to myocardial infarction is an independent risk factor for
reduced long-term survival. Late effects of correction of mitral incompetence concomitant with coronary artery bypass grafting (CABG)
are less well known and the choice of mitral valve procedure is still debated. Methods: From 1988 to 1998, 93 consecutive patients (mean
age 63 ^ 9 years) were treated for moderate to severe irreversible mitral regurgitation secondary to myocardial infarction; 84 were in NYHA
functional class III–IV and 19 were in cardiogenic shock. Thirty-seven patients underwent emergency surgery. Perioperative intraaortic
balloon pump (IABP) was necessary in 33 patients. Follow-up ranged from 6 months to 12 years (mean 51 months ^ 41). Results: Mitral
valve was repaired in 30 patients and replaced in 63. Replacement was preferably performed in patients with major displacement of papillary
muscle and in patients with acute papillary muscle rupture. CABG (3.4 distal anastomoses) was performed in all patients and was complete in
92%. Early mortality was 15% (14/93). Multivariable analysis identified need for IABP ðP ¼ 0:005Þ and COPD ðP ¼ 0:02Þ as risk factors for
early death. Emergency surgery had only a trend ðP ¼ 0:15Þ for increased mortality; age, low ejection fraction, repair vs. replacement had no
influence. Actuarial survival rates at 1, 5 and 10 years were 81, 65 and 56%, respectively. Late survival was similar in patients with
replacement or repair ðP ¼ 0:46Þ. At last follow-up, all but one patient were in NYHA functional class I or II. Conclusions: Combined mitral
valve procedure and myocardial revascularization, as complete as possible, for moderate to severe mitral regurgitation secondary to
myocardial infarction achieve satisfactory early and late outcome despite the increased operative mortality. Acute papillary muscle rupture,
severe restriction of the mitral valve by major displacement of the papillary muscle are better managed by valve replacement. q 2002
Elsevier Science B.V. All rights reserved.
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1. Introduction
Mitral regurgitation secondary to myocardial infarction is
a common clinical problem, developing after myocardial
infarction in up to 19% of patients [1]. Uncorrected moder-
ate to severe mitral regurgitation secondary to myocardial
infarction during coronary artery bypass grafting (CABG) is
an independent risk factor for long-term survival [1–3].
Catheter-based reperfusion with thrombolysis or coronary
angioplasty does not reliably reverse valvular incompetence
nor does it reduce mortality to the levels experienced by
patients with lesser degrees of mitral regurgitation [4].
Thus, an increasing number of patients with moderate to
severe mitral regurgitation secondary to myocardial infarc-
tion require combined surgical procedures to revascularize
the ischemic myocardium and to restore mitral valve
competence. However, late effects of correction of mitral
incompetence concomitant with CABG are less well known
[5–8] and the choice of mitral valve procedure is still
debated. In this study, we report the results of combined
mitral valve and coronary artery bypass procedures, and
our indications for the choice of mitral valve procedure in
specific subsets of these patients.
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2. Patients and methods
2.1. Definitions
Mitral valve regurgitation secondary to myocardial
infarction was documented angiographically and/or echo-
cardiographically and graded by taking into account several
echocardiographic criteria [7,9–11]:
† the proximal jet diameter measured in the cross-section
in which the minimal diameter of the mitral regurgitation
on the atrial side appeared the largest, a diameter of
.6.5 mm relates to mitral regurgitation grades 3 and 4.
The radius of the proximal isovelocity hemicircle with a
Nyquist limit set at 35–40 cm/s helps to differentiate
between grade 2 (0–3 mm), grade 3 (3–9 mm) and
grade 4 (.9 mm);
† the color Doppler jet area: 0–1.5 cm2 for grade 1, 1.5–
3 cm2 for grade 2, 3–6 cm2 for grade 3,.6 cm2 for grade
4;
† the intensity of the continuous flow Doppler. The density
and completeness of a continuous wave signal from a
regurgitant jet is a function of the angle at which the
jet is interrogated and the number of reflecting red cells
flowing through the laminar core. In grade 4 mitral regur-
gitation, if the proper interrogation angle is obtainable,
the regurgitant jet is dense and has a sharp border or
envelope;
† the systolic Doppler flow in the pulmonary veins: the
pulmonary flow is normally maximal during early
systole. Trivial grade 1 mitral regurgitation does not
alter the pulmonary vein flow, but as mitral regurgitation
reaches moderate and severe degrees, systolic inflow
becomes progressively blunted. In severe grade 4 mitral
regurgitation the flow reverses; it is biphasic in moderate
grade 3 mitral regurgitation and only diminished in mild
grade 2 mitral regurgitation.
In this study, indication for mitral valve surgery was
grade 3 or grade 4 irreversible mitral regurgitation second-
ary to myocardial infarction. All five patients who under-
went combined mitral valve and revascularization
procedures because of inability to discontinue the cardio-
pulmonary bypass after isolated revascularization, had
grade 2 mitral regurgitation preoperatively. Otherwise,
this study does not deal with grade 2 mitral regurgitation
secondary to myocardial infarction.
Coronary stenosis was considered significant if there was
a 70% or greater stenosis in the luminal diameter in any
view. A stenosis of 50% or more in the left main coronary
artery was considered significant [3].
Patients were excluded if there was evidence of other
mitral valve pathology. Mitral valve regurgitation secondary
to myocardial infarction was considered acute if the interval
between myocardial infarction and operation was less than 4
weeks and chronic if the interval was greater [3,12].
Patients were considered to undergo salvage operation
when brought to the operating room (OR) under cardiopul-
monary resuscitation, emergency operation when brought to
the OR directly from the cath lab or intensive care unit
because of hemodynamic instability, urgent operation
when operated on during the same hospitalization as for
angiography because their discharge was deemed medically
unreasonable [13]. Otherwise the operation was considered
elective.
The pathogenesis of mitral valve regurgitation was clas-
sified according to previous reports [14–16]. Leaflet
prolapse could result from papillary muscle infarction
with secondary elongation and possible chordae rupture
due to altered collagen concentration [17], or by papillary
muscle rupture. Restrictive leaflet motion could be due to
regional papillary muscle-annular dysfunction-complex, or
due to diffuse left ventricular dysfunction with generalized
ventricular and mitral annular dilatation.
Left ventricular function was assessed by ventriculogra-
phy or echocardiography, or both, and categorized as
normal ðEF . 0:5Þ, moderately impaired ðEF ¼ 0:32 0:5Þ
or severely impaired ðEF , 0:3Þ [18].
Mortality and morbidity rates are reported according to
the guidelines of the Ad Hoc Liaison Committee for Stan-
dardizing Definitions of Prosthetic Heart Valve Morbidity
of The Society of Thoracic Surgeons and The American
Association for Thoracic Surgery [19].
2.2. Patient characteristics
Between January 1988 and December 1998, 263 conse-
cutive patients underwent combined mitral valve procedure
and CABG at our institution. Of these, 93 (35%) had mitral
regurgitation secondary to myocardial infarction and form
the basis of this report.
Patients characteristics are listed in Table 1. Eighty-four
patients (90%) were in NYHA functional class III or IV. A
history of congestive heart failure was present in 65 patients
(70%). Seven patients had undergone open heart surgery
previously. Nineteen patients (20%) underwent operation
while in cardiogenic shock. Three patients underwent
salvage operation, whereas 16 were operated upon on an
emergency basis. Eighteen other patients (19%) underwent
operation on an urgent basis. Intraaortic balloon pump
(IABP) was needed in 33 patients (35%) perioperatively.
It was inserted in 19 patients who were preoperatively in
cardiogenic shock with a systolic arterial blood pressure of
,80 mm Hg (or a decrease of more than one-third of the
usual values of the patient for systolic blood pressure) and
urine output of less than 300 ml/24 h. In 12 other patients
IABP was inserted intraoperatively because of inability to
discontinue the cardiopulmonary bypass. In two patients
IABP was inserted on the first postoperative day because
of hemodynamic deterioration due to ongoing myocardial
infarction (in one patient) and bleeding (in another patient).
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Thirty-one patients (33%) presented with acute myocardial
infarction.
The mean EF was 0.46 ^ 0.14, 20% of patients having
severely depressed and 41% moderately depressed left
ventricular function. Fifty-four patients had 3-vessel
disease, 25 2-vessel disease and 14 1-vessel disease (with
involvement of the inferior left ventricular wall). Left main
disease was present in five. The majority of patients (95%)
had moderate (13) to severe (14) mitral regurgitation.
The mechanism of mitral regurgitation is listed in Table
2. ‘Regional papillary-muscle-annular dysfunction
complex’ relates to a lack of coaptation of leaflets caused
by an inferior myocardial infarction with secondary remo-
deling of the left ventricular wall supporting the posterome-
dial papillary muscle, and annular dilatation. The
remodeling process of the left ventricular wall and the papil-
lary muscle can distort and displace the posterior papillary
muscle toward the apex.
2.3. Statistical analysis
Continuous variables are expressed as mean ^ 1SD.
Categorical variables are presented as percentages. Univari-
ate analysis is done with the use of x 2 and Fisher-exact tests
as appropriate. Multivariate logistic regression analysis was
used to identify independent predictors of early survival.
Survival curves are presented according to the method of
Kaplan and Meier. Combinations of variables related to late
survival and freedom from other events are examined using
Cox proportional-hazard regression. A P value ,0.05 was
considered to show a statistically significant difference. All
calculations were done with the use of a commercially avail-
able statistical program (SPSS 9.0).
Follow-up ranged from 6 months to 12 years (mean 51
months ^ 41).
3. Results
3.1. Intraoperative variables (Table 3)
Patients were operated on under moderate hypothermia
(26–328C) and antegrade or combined antegrade and retro-
grade blood cardioplegia. Five patients had their operation
done under induced ventricular fibrillation without aortic
cross-clamping. The reasons were calcified plaques of the
ascending aorta and dense periaortic adhesions after
previous open heart surgery. In each case the surgeon esti-
mated it safer not to clamp the ascending aorta. The prox-
imal bypass graft anastomoses were performed either to the
previous vein grafts or to one of the internal thoracic
arteries. The mean cross-clamp time was 81.2 ^ 35.9 min
(range 41–154), the mean cardiopulmonary bypass time
151.1 ^ 61.0 min (range 74–476). CABG was done first
and additional cardioplegia delivery was routed through
the vein grafts. Revascularization was complete in 86
patients (92%). The LAD was revascularized in 73 patients
(74% with the LIMA). The average distal anastomoses/
patient was 3.43 ^ 1.62.
Mitral valve replacement ðn ¼ 63Þ was done in most
instances with posterior chordal preservation. Bileaflet
mechanical valves were used in 59 patients and biological
valves in four (Carpentier-Edwards). Acute rupture of a
papillary muscle head causes prolapse of the anterior leaflet,
more often than the posterior leaflet. Mitral valve repair is
difficult in these patients because of the fragility of the
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Table 2
Mechanism of mitral regurgitation
N %
Prolapse
Chordal avulsion and ischemic elongated papillary
muscle
10 11
Papillary muscle rupture 21 23
Restrictive leaflet motion
Regional papillary muscle-annular complex dysfunction 43 46
Global left ventricular dysfunction 19 20
Table 3
Intraoperative variables ðn ¼ 93Þ
N Range
Cross-clamp time (min) 81.2 ^ 35.9 41–154
Bypass time (min) 151.1 ^ 61.0 74–476
Number of distal anastomoses/patient 3.4 ^ 1.6 1–9
LAD revascularized 73 (78%)
LIMA 54 (74%)
Complete revascularization 86 (92%)
Mitral valve repair 30 (32%)
Mitral valve replacement 63 (68%)
Table 1
Patient characteristics (PAP, pulmonary artery pressure; PWP, pulmonary
wedge pressure)
Age 63.5 ^ 8.9 yr (range 39–78)
Gender (male/female) 68 (73%)/25 (27%)
NYHA (mean) 3.5 ^ 0.7
II 9 (10%)
III 32 (34%)
IV 52 (56%)
Congestive heart failure history 65 (70%)
Diabetes 9 (10%)
Chronic obstructive disease 5 (5%)
Chronic renal failure/dialysis 4 (4%)
Previous open heart surgery 7 (8%)
Acute presentation 31 (33%)
Preoperative arrhythmia 49 (53%)
Shock 19 (20%)
Status
Elective 55 (59%)
Urgent 19 (21%)
Emergency 16 (17%)
Salvage 3 (3%)
Intraaortic balloon pumping 33 (35%)
Preoperative PAP mean (mmHg) 30 ^ 13
Preoperative PWP (mmHg) 18 ^ 8
necrotic tissue and because of uncertainties related to left
ventricular wall remodeling after acute myocardial infarc-
tion. In these patients we performed preferably mitral valve
replacement with preservation of chordae tendinae of the
posterior leaflet.
Mitral valve repair, when attempted, was conducted
according to various techniques previously described [20–
22]. Downsizing ring annuloplasty alone [23] was under-
taken in six patients. Mitral valve repair was attempted in 42
patients and was successful (by reducing mitral regurgita-
tion by at least 2 grade) in 30 patients. Chordal avulsion and
ischemic elongated papillary muscle were repaired by
partial resection and readaptation of the leaflet edges and
by plication of the papillary muscle. Wooler annuloplasty or
Carpentier ring annuloplasty was added to the repair in
presence of annular dilatation. Global left ventricular
dysfunction and dilatation of the mitral annulus were
repaired earlier in the series by Wooler annuloplasty [20]
and later on by downsizing annuloplasty [23].
Patients with regional papillary muscle-annular dysfunc-
tion were the most difficult subset of patients in this series.
Ten of 12 repair failure belonged to this group. Failed tech-
niques included Wooler annuloplasty [20], Carpentier ring
annuloplasty and Alfieri stitch [21]. The reason of failure
was extended scarring of the papillary muscle and the
supporting left ventricular wall resulting in severe restric-
tion of the valve by major distortion and apical displacement
of the papillary muscle with excessive increase in the papil-
lary muscle-mitral annulus distance. Subsequently, we
performed mitral valve replacement in these patients unless
the increase in the distance between the tip of the papillary
muscle and the mitral annulus was not excessive. In the
latter cases an asymmetrical posteromedial Wooler annulo-
plasty (for posteromedial papillary muscle scarring) was
carried out.
The mean postrepair residual mitral regurgitation as
controlled by intraoperative transesophageal echocardiogra-
phy was 0.6 ^ 1.0. Only four patients left the OR with resi-
dual grade 2 mitral regurgitation.
Associated procedures are listed in Table 4.
3.2. Outcome
There were 14 in-hospital deaths (15%). Two patients
died of sepsis and multiorgan failure. Cerebrovascular insult
was the cause of death in two patients. Five patients died of
cardiac failure. Bleeding was the cause of death in three
patients (two due to postoperative ventricular rupture). Peri-
operative myocardial infarction accounted for the two other
in-hospital deaths.
Early mortality tended to be higher in patients undergoing
emergency (8/37 ¼ 22%) vs. elective surgery (6/56 ¼ 11%,
P ¼ 0:15), as well as in patients in functional class IV (11/
52 (21%) vs. 3/41 (7%), P ¼ 0:06). Preoperative ejection
fraction as a continuous variable, mechanism of mitral
regurgitation (prolapse vs. restrictive), atrial fibrillation
and age were not associated with higher early mortality
(Table 5). Duration of cardiopulmonary bypass was a risk
factor for early mortality (survivors vs. non-survivors
145 ^ 51 vs. 186 ^ 97 min, P ¼ 0:01). Early mortality
was not different after mitral valve replacement (8/
63 ¼ 12.7%) vs. repair (6/30 ¼ 20%, P ¼ 0:3). Other
univariate risk factors for early mortality included perio-
perative use of IABP (10/33 (30%) vs. 4/60 (7%),
P ¼ 0:002) and chronic pulmonary obstructive disease (3/
5 (60%) vs. 11/88 (13%), P ¼ 0:004). In multivariate analy-
sis perioperative use of IABP (odds ratio ¼ 7.4 P ¼ 0:005)
and chronic pulmonary obstructive disease (odds
ratio ¼ 15.4, P ¼ 0:02) remained independent predictors
of early mortality.
Perioperative morbidity in 79 survivors included inotro-
pic and respiratory support more than 24 h in 36 (46%) and
32 (41%) patients, respectively. Reexploration for bleeding
was done in six patients (8%). Six patients had a cerebro-
vascular insult (8%) and four a perioperative myocardial
infarction (5%). Wound debridement for mediastinitis was
necessary in three patients (4%). Four patients (5%)
required dialysis postoperatively.
Late death occurred in 20 patients, of which ten were
directly cardiac related and five of unknown origin. Actuar-
ial survival rates at 1, 5 and 10 years were 81, 65 and 56%,
respectively (Fig. 1). Late survival was not significantly
different in patients after replacement vs. repair
ðP ¼ 0:46Þ, but COPD (hazard ratio ¼ 4.0, P ¼ 0:02) and
use of IABP (hazard ratio ¼ 2.6, P ¼ 0:003) remained as
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Table 4
Associated procedures
N
Aortic valve replacement 8
Ascending aorta patch repair 1
Left ventricular aneurysmectomy 6
Atrial septum defect closure 1
Tricuspid valve repair 1
Table 5
Univariate analysis of hospital death (PAP, pulmonary artery pressure;
PWP, pulmonary wedge pressure)
P value
Age. 70 yr 0.7
NYHA IV 0.06
Ejection fraction 0.9
Emergency 0.15
Chronic obstructive pulmonary disease 0.004
Preoperative arrhythmia 0.1
Grade 4 mitral regurgitation 0.4
PAP mean (mmHg) 0.28
PWP (mmHg) 0.33
IABP 0.002
Cardiopulmonary bypass (min) 0.01
Valve replacement/repair 0.3
independent predictors of decreased late survival. Fig. 2
shows the actuarial survival of patients with and without
perioperative IABP. Three (two mitral valve replacements,
one CABG) patients required reoperation during follow-up,
resulting in a freedom from reoperation of 98, 98 and 95% at
1, 5 and 10 years, respectively. At last follow-up, all but one
patient were in NYHA functional class I or II.
4. Discussion
Uncorrected moderate to severe mitral regurgitation
secondary to myocardial infarction has been demonstrated
to have an adverse influence on survival [1–3]. Previous
reports have shown that surgical management of important
mitral regurgitation secondary to myocardial infarction with
CABG alone is suboptimal [3,7]. However, patients under-
going combined mitral valve procedure and CABG are at
higher risk for operative death as compared to those under-
going isolated procedures [5]. In this study early mortality
was 15%, which compares to 14.6% for Dion et al. [24], 9.3%
for Cohn et al. [6], 9.2% for Hendren et al. [12] and 15.3%
overall operative mortality for mitral valve replacement and
coronary artery bypass in the STS database [5]. Early mortal-
ity tended to be higher in patients undergoing emergency
surgery and in patients in preoperative functional class IV.
In the STS database both factors were associated with higher
operative mortality [5]. In univariate analysis the duration of
cardiopulmonary bypass had a significant negative impact on
early mortality. In multivariate analysis, however, the only
independent risk factors for early mortality were need for
perioperative IABP and COPD. Hendren et al. [12] from
the Cleveland Clinic reported preoperative use of IABP to
be associated with increased operative mortality. This find-
ing underlines the negative impact of the preoperative
compromised hemodynamics on early mortality. Unlike
Hausmann et al. [8], we did not find preoperative ejection
fraction as risk factor for early death. One explanation for this
finding is that preoperative ejection fraction does not take
into account hibernating myocardium which will recover
after revascularization.
The 5-year survival rate in our patients is 65%, comparing
with 71% for Cohn et al. [6] and 63% 3-year survival rate
for the Cleveland Clinic [12].
There was no significant impact of the specific valve
pathology (prolapse vs. restrictive) or mitral valve procedure
(repair versus replacement) on late survival in our series. This
is in accordance with the findings of other series [6,12].
Hendren et al. [12] reported an in-hospital death ratio of
11.5% for prolapse vs. 7.7% for restrictive (not significant)
and could not identify significant risk factors using multi-
variate analyses. Univariate analysis in their study identified
restrictive leaflet motion ðP ¼ 0:02Þ, incomplete revascular-
ization ðP ¼ 0:01Þ, perioperative stroke ðP ¼ 0:002Þ, perio-
perative myocardial infarction ðP ¼ 0:01Þ, perioperative
renal failure ðP , 0:01Þ, prolonged postoperative respiratory
insufficiency ðP ¼ 0:006Þ, preoperative intraaortic balloon
pump ðP , 0:001Þ as predictors of late mortality but multi-
variate analysis could not identify independent predictors of
late mortality. In their study patients with restrictive pathol-
ogy tended to fair less well after repair. Cohn et al. [6]
reported an operative mortality of 9.5% for the repair
group compared to 8.9% for the replacement group
ðP ¼ nsÞ. There was a trend for a higher operative mortality
for the functional group, and for the annular dilatation
subgroup who had repair, but this was not significant. No
predictors of operative mortality were identified by multi-
variate logistic regression analysis. In their study functional
ischemic mitral regurgitation was classified as due to annular
dilatation or restrictive leaflet motion. Mechanical or struc-
tural ischemic mitral regurgitation was classified as due to
chordae rupture or desinsertion, and to partial or complete
papillary muscle rupture. The overall 5-year survival rate
was 91 ^ 5% for the mitral valve replacement group and
56 ^ 10% for the mitral valve repair group ðP ¼ 0:01Þ. The
overall 5-year survival rate for the functional group was
61 ^ 10% and was not significantly different from that for
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Fig. 1. Kaplan–Meier actuarial survival for the entire group.
Fig. 2. Actuarial survival in patients with and without the need for preo-
perative IABP, showing a significantly worse outcome in those with IABP,
particularly early after operation.
the structural group, which was 83 ^ 7% ðP ¼ 0:2Þ. In the
study of Cohn et al. [6] multivariate logistic regression analy-
sis identified mitral valve repair to be a significant predictor
for worse long-term survival ðP ¼ 0:014Þ. On further analy-
sis, mitral valve repair was found to be a surrogate for the
functional ischemic mitral regurgitation group which under-
went repair ðP ¼ 0:003Þ, who were directly responsible for
the worse outcomes in the overall mitral valve repair group.
This observation of Cohn et al. supports our finding that
severe restriction with excessive increase in the papillary
muscle-mitral annulus distance, and major annular dilatation
are better managed by mitral valve replacement.
We recommend correction of moderate grade 3 to severe
grade 4 mitral regurgitation secondary to myocardial infarc-
tion during the coronary artery bypass surgery. Although the
combined mitral valve and revascularization procedure
entails a significant operative risk, especially in emergency
situations, the long-term benefit is substantial both in terms
of survival and functional capacity. The conclusion of
‘benefit in terms of functional capacity’ is derived from
the fact that 90% of our patients were preoperatively in
functional class III or IV and postoperatively all but one
survivors to follow-up in functional class I or II. The conclu-
sion of ‘benefit in terms of survival’ is based on the obser-
vations of Adler et al. [2] reporting that important ischemic
mitral regurgitation ($12) left uncorrected during coronary
artery bypass surgery is an independent risk factor for early
and late mortality, as well as on those of Connolly et al. [3]
showing that increasing severity of uncorrected ischemic
mitral regurgitation during coronary artery bypass surgery
correlated with increased early and late mortality. More-
over, Hickey et al. [1] showed that 5-year survival rate of
patients with grades 3 and 4 ischemic mitral regurgitation
treated medically was 40%. Our observed 5-year survival
rate of 65% indicates a survival benefit of our surgical
management compared to medical treatment in the report
of Hickey et al. [1]. The limitations of our study are all those
of retrospective studies. We did not directly compare the
effect of bypass alone to combined mitral valve and bypass
procedure in these patients. However, since grades 3 and 4
mitral regurgitation secondary to myocardial infarction are
to us and other authors [1–3] indication for surgical correc-
tion, a prospective randomization of these patients to two
arms with and without surgical correction of mitral regur-
gitation would seem unethical. The observation of Tcheng
et al. [4] supports further this assertion in that they reported
that patients with grades 3 and 4 ischemic mitral regurgita-
tion had a spontaneous mortality rate of 52% at 1 year.
In conclusion, we recommend combined mitral valve
procedure and myocardial revascularization, as complete
as possible, for grade 3 and grade 4 mitral regurgitation
secondary to myocardial infarction. The choice of mitral
valve procedure should be adapted to the local anatomical
findings. In our opinion acute papillary muscle rupture,
severe restriction of the mitral valve by extended scarring
of the papillary muscle and the supporting left ventricular
wall resulting in major distortion and apical displacement of
the papillary muscle with excessive increase in the papillary
muscle-mitral annulus distance, and major annular dilata-
tion are indications for mitral valve replacement. Patients
with annular dilatation alone and patients with chordal avul-
sion and ischemic elongated papillary muscle could be satis-
factorily repaired.
References
[1] Hickey MStJ, Smith RL, Muhlbaier LH, Harrell FE, Reves JG, Hino-
hara T, Califf RM, Pryor DB, Rankin JS. Current prognosis of
ischemic mitral regurgitation: implication for future management.
Circulation 1988;78(Suppl 1):51–59.
[2] Adler DS, Goldman S, O’Neil A, Cook EF, Mudge GH, Shemin RJ,
Disesa V, Cohn LH, Collins JJ. Long-term survival of more than 2000
patients after coronary artery bypass grafting. Am J Cardiol
1986;58:195–202.
[3] Connolly MW, Gelbfish JS, Jacobowitz IJ, Rose DM, Mendelsohn A,
Cappabianca PM, Acinapura AJ, Cunningham JN. Surgical results for
mitral regurgitation from coronary artery disease. J Thorac Cardio-
vasc Surg 1986;91:379–388.
[4] Tcheng JE, Jackman JD, Nelson CL, Gardner LH, Smith LR, Rankin
JS, Califf RM, Stack RS. Outcome of patients sustaining acute
ischemic mitral regurgitation during myocardial infarction. Ann
Intern Med 1992;117:18–24.
[5] Jamieson WER, Edwards FH, Schwartz M, Bero JW, Clarck RE,
Grover FL, for the Database Committee of the Society of Thoracic
Surgeons. Risk stratification for cardiac valve replacement. National
cardiac surgery database. Ann Thorac Surg 1999;67:943–951.
[6] Cohn LH, Rizzo RJ, Adams DH, Couper GS, Sullivan TE, Collins JJ,
Aranki SF. The effect of pathophysiology on the surgical treatment of
ischemic mitral regurgitation: operative and late risks of repair versus
replacement. Eur J Cardiothorac Surg 1995;9:568–574.
[7] Czer LSC, Maurer G, Bolger AF, De Robertis M, Chaux A, Matloff
JM. Revascularization alone or combined with suture annuloplasty for
ischemic mitral regurgitation. Tex Heart Inst J 1996;23:270–278.
[8] Hausmann H, Siniawski H, Hotz H, Hofmeister J, Chavez T, Schmidt
G, Hetzer R. Mitral reconstruction and mitral valve replacement for
ischemic mitral insufficiency. J Card Surg 1997;12:8–14.
[9] Sheikh KH, Bengtson JR, Rankin JS, de Bruijn NP, Kisslo J. Intrao-
prative transesophageal doppler color flow imaging used to guide
patient selection and operative treatment of ischemic mitral regurgi-
tation. Circulation 1991;84:594–604.
[10] Flachskampf FA, Frieske R, Engelhard B, Grenner H, Frielingsdorf J,
Beck, Reineke T, Thomas JD, Hanrath P. Comparison of transeso-
phageal Doppler methods with angiography for evaluation of the
severity of mitral regurgitation. J Am Soc Echocardiogr
1998;11:882–892.
[11] Schiller NB, Foster E, Redberg RF. Transesophageal echocardiogra-
phy in the evaluation of mitral regurgitation: the twenty-four signs of
severe mitral regurgitation. Cardiol Clin 1993;11:399–408.
[12] Hendren WG, Nemec JJ, Lytle BW, Loop FD, Taylor PC, Stewart
RW, Cosgrove III DM. Mitral valve repair for ischemic mitral insuf-
ficiency. Ann Thorac Surg 1991;52:1246–1252.
[13] Grover FL, Hammermeister KE, Burchfiel C, cardiac surgeons of the
department of veteran affairs. Initial report of the veteran administra-
tion preoperative risk assessment study for cardiac surgery. Ann
Thorac Surg 1990;50:12–28.
[14] Rankin JS. Improving surgical strategies for ischemic mitral regurgi-
tation. J Heart Valve Dis 1993;2:533–535.
[15] David TE. Techniques and results of mitral valve repair for ischemic
mitral regurgitation. J Card Surg 1994;9(Suppl):274–277.
R. Tavakoli et al. / European Journal of Cardio-thoracic Surgery 21 (2002) 818–824 823
[16] Dion R. Ischemic mitral regurgitation: when and how should it be
corrected? J Heart Valve Dis 1993;2:536–543.
[17] Kunzelmann KS, Quick DW, Cochran RP. Altered collagen concen-
tration in mitral valve leaflets: biochemical and finite element analy-
sis. Ann Thorac Surg 1998;66:S198–S205.
[18] Nashef SAM, Roques F, Gauduscheau E, Lemeshow S, Salamon R, the
EuroSCORE study Group. European system for cardiac operative risk
evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999;16:9–13.
[19] Edmunds HL, Clark RE, Cohn LH, Grunkemeier GL, Miller DC,
Weisel RD. Guidelines for reporting morbidity and mortality after
cardiac valvular operations. Ann Thorac Surg 1996;62:932–935.
[20] Wooler GH, Nixon PGF, Grimshaw VA, Watson DA. Experience
with the repair of mitral valve in mitral incompetence. Thorax
1962;17:49–56.
[21] Fucci C, Sandrelli L, Pardini A, Torracca L, Ferrari M, Alfieri O.
Improved results with mitral valve repair using new surgical techni-
ques. Eur J Cardiothorac Surg 1995;9:621–627.
[22] Carpentier A, Chauvaud S, Fabiani JN, Deloche A, Relland J, Lessana
A, D’Allaines Cl, Blondeau Ph, Piwnica A, Dubost Ch. Reconstruc-
tive surgery of mitral valve incompetence. J Thorac Cardiovasc Surg
1980;79:338–348.
[23] Bolling SF, Deeb GM, Brunsting LA, Bach DS. Early outcome of
mitral valve reconstruction in patients with end-stage cardiomyopa-
thy. J Thorac Cardiovasc Surg 1995;109:676–683.
[24] Dion R, Benetis R, Elias B, Guennaoui T, Raphael D, Van Dyck M,
Noirhomme Ph, Van Overschelde JL. Mitrale valve procedure in
ischemic regurgitation. J Heart Valve Dis 1995;4(Suppl II):S124–S131.
Appendix. Conference discussion
Dr B. Messmer (Aachen, Germany): We just published in the August
Journal of the Association a paper with the same topic, and we had a
mortality of 19% in the ischemic and it was 6.5% in the nonischemic
disease, combined mitral and coronaries. But what we have seen, I think
this was a little bit surprising, that once early mortality was out for the long-
term survival, it was quite similar for the patients who had mitral valve
replacement or repair for ischemic combined with the coronaries as it was
for degenerative or rheumatic disease combined with bypass surgery. So it
seems that the big difference is early after surgery, and afterwards the
patient has a very good outlook on a long-term range.
Dr Y. Zhang (Beijing, China): I have some questions. One is, what is your
selection criteria for patients for mitral valve repair and valve replacement?
And the second, I think that your mortality is a little bit higher. If the
patient is too weak to tolerate the combined procedure, how do you think
just to leave the mitral valve untreated and do coronary artery bypass by a
hybrid procedure, just the MIDCAB plus PTCA?
Dr Tavakoli: The first question is repair versus replacement. We tried
repair in 42 patients with 30 patients successfully weaned from cardiopul-
monary bypass. What does it mean successfully and what are the criteria?
At this point it is very difficult to be sure what we should do with the
residual mitral regurgitation. There is a paper from the Cleveland Clinic
for a couple of years which shows patients with a 12 mitral residual
regurgitation come back more often to reoperation late after operation.
So our aim was to achieve a residual mitral regurgitation 0 to 11 . And
regarding the criteria, we think patients with acute papillary muscle rupture
and patients with severe dilatation of the left ventricle and the mitral annu-
lus are not good candidates for repair.
Would you please repeat your second question?
Dr Zhang: The patient is too weak to tolerate the combined procedure.
What do you think about the hybrid procedure?
Dr Tavakoli: I think there is enough evidence in the literature that
important mitral regurgitation left uncorrected affects severely the early
outcome. So you have to address both problems. We have no experience
with the hybrid procedure. That means valve procedure and …
Dr Zhang: No. MIDCAB plus PTCA.
Dr Tavakoli: We have no experience with hybrid myocardial revascu-
larization in this situation.
Dr Zhang: How do you think about the size of left atrium and left
ventricle and the future of the patient for symptoms is heart failure symp-
toms, do you think it is also included in the criteria for selection of the
patients?
Dr Tavakoli: I think the impact of a history of heart failure for the
surgeon in the OR was practically a question of the degree of dilatation
of the left ventricle and the mitral annulus. We did in six patients a down-
sizing annuloplasty, as advocated by Steven Bolling, but we feel uncom-
fortable to do it in patients with severely dilated ventricles.
Dr H. Azar: (Norfolk, VA, USA): I wonder if you tried to analyze your
patients in two separate groups, namely the ones who have acute mitral
regurgitation in conjunction with coronary artery disease and a larger group
that have chronic mitral regurgitation and see how that differs, because I
think it is the second group that is going to be more in question of when to
intervene and what sort of results you get.
Dr Tavakoli: I think we have not enough patients to compare acute
versus chronic ischemic mitral regurgitation. This is some thing that should
be done. But our impression is the preoperative hemodynamic compromise
of the patient is reflected through the need for intra-aortic balloon pumping,
for example, which is at least one of the determinant factors of early and
late outcome.
Dr W. Binafsihi (Jakarta, Indonesia): I am just wondering if any of those
patients could have sparring of their cords of the papillary muscle of the mitral?
Dr Tavakoli: Is the question if any patients received an artificial cord?
Dr Binafsihi: No. Could any of those patients have any potential sparring
of the cords?
Dr Tavakoli: You mean during the valve replacement?
Dr Binafsihi: Yes.
Dr Tavakoli: In most instances the valve replacement was conducted
with preserving at least the posterior leaflet.
Dr Messmer: I think this is very important, especially in the ischemic
disease, that you keep as much suspension as you can.
Mr R. Akar (Leicester, UK): Mr. Azar from Virginia suggested that
ischemic mitrals should be evaluated acute and chronic. I entirely agree
with that, and I would like to add prolapse and restrictive ischemic mitrals
has got a different prognosis as well from our series. May I ask, do you
tackle grade II ischemic mitral regurgitation? You mentioned that grade III
and IV is definitely an indication for surgery. What do you do for grade II?
Dr Tavakoli: We are aware of the recommendation of Dr. Dion and other
colleagues, but we do not provoke patients with 12 mitral regurgitation in
the operating room, but we are aware of the procedure.
Mr Akar: May I suggest that Grigone from the Mayo Clinic recently,
three months ago, published his series, and same studies suggest that grade
II ischemic mitral regurgitation has got an extremely high risk in long-term
survival. So I think as surgeons we should think about tackling grade II
ischemic mitrals.
May I ask a last question, what types of mitral repairs you performed in
your repair group?
Dr Tavakoli: As I said, we used all previously described techniques by
Carpentier; we used in six patients downsizing to a 28 as advocated by
Steven Bolling; we used in recent patients, in five patients, accompanied by
a commissuroplasty, an Alfieri stitch. So we used all possible and
previously described techniques.
Mr Akar: Do you use the Alfieri stitch for ischemics?
Dr Tavakoli: Not so often. I would say in the recent patients there were
only five patients who received an Alfieri stitch.
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